Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

1681744

registered interest
date	11/01/2024
answering body	Ministry of Justice
answering dept id	54
answering dept short name	Justice
answering dept sort name	Justice
hansard heading	Prisoners: Men
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what assessment they have made of the expected combined impact on the size of the adult male prison population of the Sentencing Bill, the Criminal Justice Bill, and the Victims and Prisoners Bill.
tabling member printed	Lord Warner
uin	HL1541
answer	answer is ministerial correction date of answer 24/01/2024 answer text <p>The Government is taking action to reform the justice system and reduce the pressure felt on our prison estate through measures introduced in the Criminal Justice Bill, Sentencing Bill, and the Victims and Prisoners Bill. This is to ensure we continue to have capacity to crack down on crime, reduce reoffending, and protect the public from the most dangerous offenders.</p><p>Publishing impact assessments is routine alongside the legislative process and the current estimates for the impact of the announced measures on the future population have been published and can be found on the gov.uk pages on each Bill. As the Bills progress through Parliament, if an update to these estimates and impact assessments are required, then these will be updated and republished during Bill progress.</p> answering member printed Lord Bellamy question first answered 24/01/2024 15:42:06 answering member 4941 label Biography information for Lord Bellamy
tabling member	1732 label Biography information for Lord Warner

1679265

registered interest
date	19/12/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Surgery: Working Hours
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what proportion of acute hospital trusts in England regularly conduct NHS operations on (1) Saturdays, and (2) Sundays; and whether this information is able to be published so that patients may exercise choice.
tabling member printed	Lord Warner
uin	HL1369
answer	answer is ministerial correction date of answer 27/12/2023 answer text <p>The information requested is shown in the attached table. This is existing Hospital Episode Statistics data that is already published by NHS England.</p> answering member printed Lord Markham question first answered 27/12/2023 13:05:54 answering member 4948 label Biography information for Lord Markham attachment 1 file name 11412_PQHL1369_suppressed (2).xlsx title Attachment
tabling member	1732 label Biography information for Lord Warner

1666940

registered interest
date	24/10/2023
answering body	Department for Education
answering dept id	60
answering dept short name	Education
answering dept sort name	Education
hansard heading	Children: Health Services and Social Services
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what progress they have made with the establishment of pilot schemes to assess the feasibility of introducing a common identifier for children across health, care, and education services.
tabling member printed	Lord Warner
uin	HL10795
answer	answer is ministerial correction date of answer 26/10/2023 answer text <p>It has not proved possible to respond to this question in the time available before Prorogation. Ministers will correspond directly with the Member.</p> answering member printed Baroness Barran question first answered 26/10/2023 11:30:48 answering member 4703 label Biography information for Baroness Barran
tabling member	1732 label Biography information for Lord Warner

1664761

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the proposed update to the 2023 Statutory Scheme to control the cost of branded health services medicines, what policy options were included in the Department of Health and Social Care's long list as alternatives to the options that were included in the final consultation.
tabling member printed	Lord Warner
uin	HL10591
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>The statutory scheme consultation sets out the options under consideration. We are in the process of analysing the responses provided, including consideration of any alternative options proposed, and will update on our preferred policy approach later this year. A copy of the impact assessment is attached.</p> answering member printed Lord Markham question first answered 24/10/2023 12:17:36 answering member 4948 label Biography information for Lord Markham attachment 1 file name Statutory Scheme Impact Assessment.pdf title Statutory Scheme Impact Assessment
tabling member	1732 label Biography information for Lord Warner

1664762

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what is the evidence that the Department of Health and Social Care used to support the statement in the consultation on the Statutory Scheme to control the cost of branded health services medicines that investment in research and development in the UK was not a "net benefit".
tabling member printed	Lord Warner
uin	HL10592
answer	answer is ministerial correction date of answer 23/10/2023 answer text <p>The approach to assessing the potential impacts on investment within the statutory scheme’s impact assessment followed well-established precedent and is in line with the Green Book paragraphs 6.5 and 6.6. As such, the impact assessment considers spillover benefits of investment, with a literature review suggesting an estimated mean benefit of 34% of the overall investment, but does not account for these within the net present value calculation due to investment being one of several possible company responses to change in profitability.</p> answering member printed Lord Markham question first answered 23/10/2023 09:57:20 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1664763

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the proposed update to the 2023 Statutory Scheme to control the cost of branded health services medicines, what analysis and evidence the Department of Health and Social Care considered when it proposed to keep growth in the cost of branded medicines in real-terms decline, at 2 per cent a year.
tabling member printed	Lord Warner
uin	HL10593
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>2% allowed growth per annum represents an 80% rise in allowed growth compared to the 1.1% per annum which applied in the statutory scheme from 2019 to 2023. The proposal is consistent with the approach that underpinned the current statutory scheme’s 1.1% allowed growth, i.e., it equals the average allowed growth of the preceding voluntary scheme.</p><p>The proposed allowed growth rate considered multiple factors including the overall fiscal path. Furthermore, consideration of the pipeline of upcoming new treatments featured within our forecast growth in spend on new treatments and, ultimately, continued growth forecast in medicine sales.</p><p>Controlling growth at this level is considered to allow for a viable overall envelope for the statutory scheme more favourable for industry compared to the existing statutory scheme arrangements, whilst continuing to ensure that spend on branded medicines is affordable to the National Health Service.</p> answering member printed Lord Markham grouped question UIN HL10594 question first answered 24/10/2023 11:37:30 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1664764

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Proposed update to the 2023 Statutory Scheme to control the cost of branded medicines, whether the 2 per cent cap in growth in the cost of branded medicines was assessed against (1) inflation expectations, and (2) demographic pressures.
tabling member printed	Lord Warner
uin	HL10594
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>2% allowed growth per annum represents an 80% rise in allowed growth compared to the 1.1% per annum which applied in the statutory scheme from 2019 to 2023. The proposal is consistent with the approach that underpinned the current statutory scheme’s 1.1% allowed growth, i.e., it equals the average allowed growth of the preceding voluntary scheme.</p><p>The proposed allowed growth rate considered multiple factors including the overall fiscal path. Furthermore, consideration of the pipeline of upcoming new treatments featured within our forecast growth in spend on new treatments and, ultimately, continued growth forecast in medicine sales.</p><p>Controlling growth at this level is considered to allow for a viable overall envelope for the statutory scheme more favourable for industry compared to the existing statutory scheme arrangements, whilst continuing to ensure that spend on branded medicines is affordable to the National Health Service.</p> answering member printed Lord Markham grouped question UIN HL10593 question first answered 24/10/2023 11:37:30 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1664765

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to refer the Impact Assessment for the 2023 Statutory Scheme to control the cost of branded health services medicines to the Regulatory Policy Committee.
tabling member printed	Lord Warner
uin	HL10595
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>There are no plans to refer the statutory scheme Impact Assessment to the Regulatory Policy Committee. The proposals only impact companies which choose to sell to the National Health Service and are therefore considered to be in connection with procurement. Given this, the statutory exclusion from the Better Regulation Framework “Procurement 22(4)(b)” applies as confirmed previously by the Economic and Domestic Affairs Secretariat at the Cabinet Office.</p> answering member printed Lord Markham question first answered 24/10/2023 12:18:19 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1664766

registered interest
date	16/10/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	NHS: Drugs
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government what plans they have to introduce an end of scheme reconciliation exercise for the Statutory Scheme to control the cost of branded health services medicines.
tabling member printed	Lord Warner
uin	HL10596
answer	answer is ministerial correction date of answer 24/10/2023 answer text <p>No end of scheme reconciliation exercise was proposed in the recent consultation on updating the statutory scheme. We are in the process of considering consultation responses.</p> answering member printed Lord Markham question first answered 24/10/2023 11:37:59 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner

1654142

registered interest
date	18/07/2023
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Voluntary Scheme for Branded Medicines Pricing and Access
house id	2
legislature	25277 pref label House of Lords
question text	To ask His Majesty's Government, further to the Written Answers by Lord Markham on 27 June (HL8632, HL8633), how many Voluntary Scheme for Branded Medicines Pricing and Access-related price increase applications were submitted in each year from 2019 to 2023; and what proportion of these applications was successful in each of those years.
tabling member printed	Lord Warner
uin	HL9476
answer	answer is ministerial correction date of answer 25/07/2023 answer text <p>The following table shows the number of presentations between 2019 and 2023 to date where members of the 2019 Voluntary Scheme for Branded Medicines Pricing and Access had applied for a price increase. In addition, for 2023, price increase applications have been received for a further five presentations that are currently undergoing assessment by the Department.</p><table><tbody><tr><td><p>Year</p></td><td><p>Number of Presentations</p></td></tr><tr><td><p>2019</p></td><td><p>34</p></td></tr><tr><td><p>2020</p></td><td><p>21</p></td></tr><tr><td><p>2021</p></td><td><p>10</p></td></tr><tr><td><p>2022</p></td><td><p>107</p></td></tr><tr><td><p>2023</p></td><td><p>32</p></td></tr></tbody></table><p> </p><p>We are unable to provide the information requested on the proportion of successful applications, as such information is commercially sensitive.</p><p> </p> answering member printed Lord Markham question first answered 25/07/2023 15:09:08 answering member 4948 label Biography information for Lord Markham
tabling member	1732 label Biography information for Lord Warner